Last reviewed · How we verify
EXG34217
At a glance
| Generic name | EXG34217 |
|---|---|
| Sponsor | Elixirgen Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure (PHASE1)
- Rollover Study From EXG-US-01 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXG34217 CI brief — competitive landscape report
- EXG34217 updates RSS · CI watch RSS
- Elixirgen Therapeutics, Inc. portfolio CI